Published in Oncogene on October 15, 2007
Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure (2012) 1.30
Cancer associated human papillomaviruses. Curr Opin Virol (2012) 1.25
Papillomavirus E6 oncoproteins. Virology (2013) 1.21
Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett (2010) 1.17
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
The ESEV PDZ-binding motif of the avian influenza A virus NS1 protein protects infected cells from apoptosis by directly targeting Scribble. J Virol (2010) 1.13
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Vimentin regulates scribble activity by protecting it from proteasomal degradation. Mol Biol Cell (2009) 1.04
Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology (2010) 1.00
Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology (2008) 1.00
Small molecule inhibitors of human papillomavirus protein - protein interactions. Open Virol J (2011) 0.97
Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53. J Virol (2012) 0.96
E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res (2010) 0.90
Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses. Semin Cancer Biol (2014) 0.90
Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides. PLoS One (2015) 0.89
p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol (2011) 0.89
Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor. J Virol (2012) 0.87
Identification of the regions of the HPV 5 E6 protein involved in Bak degradation and inhibition of apoptosis. Int J Cancer (2008) 0.87
The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription. Oncogene (2011) 0.87
Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses (2012) 0.87
Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J Virol (2011) 0.85
Regulation of the DLG tumor suppressor by β-catenin. Int J Cancer (2012) 0.83
Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain. PLoS One (2013) 0.82
p53 suppresses hyper-recombination by modulating BRCA1 function. DNA Repair (Amst) (2015) 0.79
Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses. Virol J (2008) 0.79
Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait? Pathogens (2016) 0.78
Degradation of Human PDZ-Proteins by Human Alphapapillomaviruses Represents an Evolutionary Adaptation to a Novel Cellular Niche. PLoS Pathog (2015) 0.78
HPV E6 oncoprotein prevents recovery of stalled replication forks independently of p53 degradation. Cell Cycle (2009) 0.77
Mechanisms of polarity protein expression control. Curr Opin Cell Biol (2016) 0.76
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J (1987) 3.81
Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J (1988) 3.81
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
20 years of hospital admissions for peptic ulcer in England and Wales. Lancet (1981) 3.06
The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene (2001) 2.77
Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene (1999) 2.25
Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene (2000) 2.20
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology (1990) 2.17
The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene (1999) 2.11
High-resolution characterization of herpes simplex virus type 1 transcripts encoding alkaline exonuclease and a 50,000-dalton protein tentatively identified as a capsid protein. J Virol (1983) 2.07
Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev (2000) 2.01
Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol (2000) 1.97
'Speaking valve' aspiration in a laryngectomy patient. Anaesth Intensive Care (2010) 1.95
Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A (1999) 1.93
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem (1986) 1.91
Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J (1989) 1.84
Genome organization of porcine epidemic diarrhoea virus. Adv Exp Med Biol (1993) 1.78
Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene (1998) 1.78
Evaluation of a 2% chlorhexidine gluconate in 70% isopropyl alcohol skin disinfectant. J Hosp Infect (2005) 1.78
HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene (2001) 1.78
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J Gen Virol (1987) 1.78
Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene (1992) 1.76
Complete sequence (20 kilobases) of the polyprotein-encoding gene 1 of transmissible gastroenteritis virus. Virology (1995) 1.70
The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene (1992) 1.68
Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology (2000) 1.56
An outbreak of Serratia marcescens on the neonatal unit: a tale of two clones. J Hosp Infect (2006) 1.53
The values history: an innovation in surrogate medical decision-making. Law Med Health Care (1990) 1.50
Human papillomaviruses, cervical cancer and cell polarity. Oncogene (2008) 1.47
E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem (1998) 1.45
Pacemaker endocarditis. Report of 44 cases and review of the literature. Medicine (Baltimore) (1994) 1.44
Herpes simplex virus non-structural proteins. IV. Purification of the virus-induced deoxyribonuclease and characterization of the enzyme using monoclonal antibodies. J Gen Virol (1983) 1.44
Infection risk associated with a closed luer access device. J Hosp Infect (2006) 1.40
On the appropriateness of marginal models for repeated measurements in clinical trials. Stat Med (1998) 1.40
Diagnostic iodised oil embolisation of liver tumours--the Hammersmith experience. Eur J Radiol (1993) 1.38
Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J (1994) 1.37
Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol (1999) 1.32
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect (2002) 1.31
The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology (1994) 1.27
Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene (1994) 1.22
18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol (2000) 1.21
HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene (2000) 1.21
The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction. Oncogene (2010) 1.19
Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J Gen Virol (1997) 1.18
Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav Pharmacol (1999) 1.17
The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol (1995) 1.16
HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene (1999) 1.12
Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene (1997) 1.11
Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene (2008) 1.10
Epidemiology, clinical and laboratory characteristics of Staphylococcus aureus bacteraemia in a university hospital in UK. J Hosp Infect (2006) 1.09
[Long-term influence of associated arthrodesis on adjacent segments in the treatment of lumbar stenosis: a series of 127 cases with 9-year follow-up]. Rev Chir Orthop Reparatrice Appar Mot (2000) 1.08
Molecular phylogeny of eastern Pacific sea cucumbers (Echinodermata: Holothuroidea) based on mitochondrial DNA sequence. Mol Phylogenet Evol (1996) 1.07
Haemodynamic consequences of etomidate administration in elective cardiac surgery: a randomized double-blinded study. Br J Anaesth (2011) 1.07
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene (1994) 1.07
Prolactin studies in "functionless" pituitary tumours. Br Med J (1975) 1.07
Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene (2000) 1.05
Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ-ras. Int J Cancer (1988) 1.05
Lichenoid drug eruptions. J Am Acad Dermatol (1993) 1.02
Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene (1999) 1.02
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene (1996) 1.01
Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene (1993) 1.00
Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA. Virology (2001) 1.00
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem (2000) 1.00
IS1397 is active for transposition into the chromosome of Escherichia coli K-12 and inserts specifically into palindromic units of bacterial interspersed mosaic elements. J Bacteriol (1999) 0.99
HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene (1996) 0.99
Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr (2005) 0.97
Alternative splicing of human p53 transcripts. Oncogene Res (1987) 0.97
Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res (1991) 0.97
Hypoxaemia after cardiac surgery: clinical application of a model of pulmonary gas exchange. Eur J Anaesthesiol (2004) 0.97
Comparison of the genetic determinism of two key phenological traits, flowering and maturity dates, in three Prunus species: peach, apricot and sweet cherry. Heredity (Edinb) (2012) 0.96
Identification, characterization and quantitation of pyrogenic polycylic aromatic hydrocarbons and other organic compounds in tire fire products. J Chromatogr A (2006) 0.96
Increased expression of Ia antigens on B cells after neonatal induction of lymphoid chimerism in mice: role of interleukin 4. Eur J Immunol (1990) 0.95
Comparison between principal component analysis and independent component analysis in electroencephalograms modelling. Biom J (2007) 0.94
Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene (1999) 0.94
HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene (1996) 0.94
Quality assurance in preschool surveillance. Arch Dis Child (1994) 0.94
Children's ability to make probability estimates: skills revealed through application of Anderson's functional measurement methodology. Child Dev (1989) 0.94
Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1Q binding test. J Immunol Methods (1979) 0.93
Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology (1998) 0.93
Surprising sun: a new step towards a complete picture? Phys Rev Lett (2004) 0.93
Hyperactivity of donor B cells after neonatal induction of lymphoid chimerism in mice. Clin Exp Immunol (1988) 0.92
[Long-term outcome at adjacent levels of lumbar arthrodesis]. Rev Chir Orthop Reparatrice Appar Mot (1997) 0.92
Proteasome-mediated regulation of the hDlg tumour suppressor protein. J Cell Sci (2001) 0.92
Analysis of human papillomavirus sequences in cell lines recently derived from cervical cancers. Cancer Res (1988) 0.92
HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene (1995) 0.92
Repression of p53 transcriptional activity by the HPV E7 proteins. Virology (1997) 0.92
The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene (2001) 0.91
Does location matter? Rural vs urban outcomes after blood and marrow transplantation in a population-based Canadian cohort. Bone Marrow Transplant (2009) 0.91
Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation. Oncogene (2006) 0.91
Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J Immunol (2001) 0.91
The interaction between p53 and papillomaviruses. Semin Cancer Biol (1999) 0.91
Adeno-associated virus type 2 rep protein inhibits human papillomavirus type 16 E2 recruitment of the transcriptional coactivator p300. J Virol (2000) 0.90
The nursing process: the effect on patients' satisfaction with nursing care. J Adv Nurs (1987) 0.90
Angiosarcoma of the breast. Initial misdiagnosis is still common. Arch Surg (1995) 0.89
Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int J Mol Med (2000) 0.89
Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol (1993) 0.89
The cystine-stabilized alpha-helix: a common structural motif of ion-channel blocking neurotoxic peptides. Biopolymers (1991) 0.88